Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Recipient : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Collaboration
HLS Therapeutics Announces Promotional Agreement with Pfizer for Vascepa® in Canada
Details : Under terms of the Agreement, Pfizer will deploy a team across Canada to support education about Vascepa with primary care physician ("PCP") groups.
Brand Name : Vascepa
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 16, 2021
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Recipient : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Amarin
Deal Size : Not Applicable
Deal Type : Not Applicable
HLS Therapeutics Reports Positive Data from Covid-19 Outpatient Trial
Details : Vascepa COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while demonstrating a 25% reduction in high-sensitivity C-reactive protein with encouraging short-term safety and tolerability data using Vascepa lo...
Brand Name : Vascepa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 14, 2020
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Amarin
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
HLS Therapeutics Announces Health Canada Approval of PERSERIS® for the Treatment of Schizophrenia
Details : Health Canada has approved HLS Therapeutics' PERSERIS® (risperidone for extended-release injectable suspension), 90 mg and 120 mg subcutaneous injection, a novel long-acting injectable of risperidone, for the treatment of schizophrenia in adults.
Brand Name : Perseris
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 17, 2020
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Porcine recombinant Factor VIII
Therapeutic Area : Genetic Disease
Study Phase : Approved
Recipient : Takeda Pharmaceutical
Deal Size : $49.3 million
Deal Type : Acquisition
HLS Therapeutics Acquires Portfolio of Four Royalty Interest, Gains Takeda's Obizur
Details : HLS has acquired certain entities that hold the rights to a diversified portfolio of royalty interests on global sales of four different products, this includes Takeda Pharmaceutical's Obizur, a porcine recombinant Factor VIII for acquired hemophilia A.
Brand Name : Obizur
Molecule Type : Large molecule
Upfront Cash : $30.8 million
September 30, 2020
Lead Product(s) : Porcine recombinant Factor VIII
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Recipient : Takeda Pharmaceutical
Deal Size : $49.3 million
Deal Type : Acquisition
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
HLS Therapeutics Files New Drug Submission for PERSERIS® in Canada
Details : If approved by Health Canada, PERSERIS would become the first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 23, 2020
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?